Molecular approaches for improved clotting factors for hemophilia

Randal J. Kaufman, Jerry S Powell

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Hemophilia is caused by a functional deficiency of one of the coagulation proteins. Therapy for no other group of genetic diseases has seen the progress that has been made for hemophilia over the past 40 years, from a life expectancy in 1970 of ∼20 years for a boy born with severe hemophilia to essentially a normal life expectancy in 2013 with current prophylaxis therapy. However, these therapies are expensive and require IV infusions 3 to 4 times each week. These are exciting times for hemophilia because several new technologies that promise extended half-lives for factor products, with potential for improvements in quality of life for persons with hemophilia, are in late-phase clinical development.

Original languageEnglish (US)
Pages (from-to)30-36
Number of pages7
JournalHematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program
Volume2013
DOIs
StatePublished - 2013
Externally publishedYes

Fingerprint

Blood Coagulation Factors
Hemophilia A
Life Expectancy
Inborn Genetic Diseases
Therapeutics
Quality of Life
Technology
Proteins

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{ed7e6a6288854d1a86d097ea182cf40a,
title = "Molecular approaches for improved clotting factors for hemophilia",
abstract = "Hemophilia is caused by a functional deficiency of one of the coagulation proteins. Therapy for no other group of genetic diseases has seen the progress that has been made for hemophilia over the past 40 years, from a life expectancy in 1970 of ∼20 years for a boy born with severe hemophilia to essentially a normal life expectancy in 2013 with current prophylaxis therapy. However, these therapies are expensive and require IV infusions 3 to 4 times each week. These are exciting times for hemophilia because several new technologies that promise extended half-lives for factor products, with potential for improvements in quality of life for persons with hemophilia, are in late-phase clinical development.",
author = "Kaufman, {Randal J.} and Powell, {Jerry S}",
year = "2013",
doi = "10.1182/asheducation-2013.1.30",
language = "English (US)",
volume = "2013",
pages = "30--36",
journal = "Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program",
issn = "1520-4391",
publisher = "American Society of Hematology",

}

TY - JOUR

T1 - Molecular approaches for improved clotting factors for hemophilia

AU - Kaufman, Randal J.

AU - Powell, Jerry S

PY - 2013

Y1 - 2013

N2 - Hemophilia is caused by a functional deficiency of one of the coagulation proteins. Therapy for no other group of genetic diseases has seen the progress that has been made for hemophilia over the past 40 years, from a life expectancy in 1970 of ∼20 years for a boy born with severe hemophilia to essentially a normal life expectancy in 2013 with current prophylaxis therapy. However, these therapies are expensive and require IV infusions 3 to 4 times each week. These are exciting times for hemophilia because several new technologies that promise extended half-lives for factor products, with potential for improvements in quality of life for persons with hemophilia, are in late-phase clinical development.

AB - Hemophilia is caused by a functional deficiency of one of the coagulation proteins. Therapy for no other group of genetic diseases has seen the progress that has been made for hemophilia over the past 40 years, from a life expectancy in 1970 of ∼20 years for a boy born with severe hemophilia to essentially a normal life expectancy in 2013 with current prophylaxis therapy. However, these therapies are expensive and require IV infusions 3 to 4 times each week. These are exciting times for hemophilia because several new technologies that promise extended half-lives for factor products, with potential for improvements in quality of life for persons with hemophilia, are in late-phase clinical development.

UR - http://www.scopus.com/inward/record.url?scp=84907051813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907051813&partnerID=8YFLogxK

U2 - 10.1182/asheducation-2013.1.30

DO - 10.1182/asheducation-2013.1.30

M3 - Article

VL - 2013

SP - 30

EP - 36

JO - Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program

JF - Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program

SN - 1520-4391

ER -